The Fox Chase Chemical Diversity Center, Inc. (FCCDC)


The Fox Chase Chemical Diversity Center Annouces that Promentis Pharmaceuticals Inc Has Engaged FCCDC To Conduct Medicinal Chemistry Efforts.


Doylestown, PA. June 27, 2013- FCCDC is pleased to announce that Promentis Pharmaceuticals, Inc,a private, emerging pharmaceutical company focused on developing a therapeutic platform for neuropsychiatric disorders, with an initial emphasis on creating drugs for the treatment of schizophrenia(, has engaged FCCDC to conduct medicinal chemistry efforts to support the therapeutic developmentgoals of Promentis.